ALCLS Share Price

Open 21.17 Change Price %
High 21.52 1 Day 0.20 0.95
Low 20.85 1 Week -0.38 -1.76
Close 21.24 1 Month 4.86 29.67
Volume 67669 1 Year 1.38 6.95
52 Week High 30.14
52 Week Low 14.08
ALCLS Important Levels
Resistance 2 21.86
Resistance 1 21.61
Pivot 21.20
Support 1 20.87
Support 2 20.62
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
ALNEV 0.98 18.07%
AVQ 0.33 0.00%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
More..
EPA France Top Gainers Stocks
FLO 1.20 20.00%
FLO 1.20 20.00%
ALNEV 0.98 18.07%
APAM 33.78 15.72%
APAM 33.78 15.72%
MLLOI 3.80 15.15%
ALSPO 1.29 14.16%
DEXB 17.47 13.89%
DEXB 17.47 13.89%
MT 4.53 12.97%
More..
EPA France Top Losers Stocks
MLLEM 0.39 -38.10%
MLION 0.03 -25.00%
ALADO 0.06 -14.29%
AVT 0.09 -10.00%
AVT 0.09 -10.00%
AVT 0.09 -10.00%
AVT 0.09 -10.00%
ALEUP 0.28 -9.68%
MLRAM 40.00 -9.38%
ALDV 0.11 -8.33%
More..

Cellectis SA (EPA: ALCLS)

ALCLS Technical Analysis 2
As on 21st Feb 2017 ALCLS Share Price closed @ 21.24 and we RECOMMEND Sell for LONG-TERM with Stoploss of 21.54 & Strong Buy for SHORT-TERM with Stoploss of 17.63 we also expect STOCK to react on Following IMPORTANT LEVELS.
ALCLS Target for February
1st Target up-side 17.78
2nd Target up-side 18.77
3rd Target up-side 19.76
1st Target down-side 14.94
2nd Target down-side 13.95
3rd Target down-side 12.96
ALCLS Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.cellectis.com
ALCLS Address
ALCLS
8 rue de la Croix Jarry
Paris, 75013
France
Phone: 33 1 81 69 16 00
ALCLS Latest News
The Brokerages Set Cellectis SA (CLLS) Target Price at the $46.60   DailyQuint   - 15th Feb 17
Abingworth LLP Continues to Hold Stake in Cellectis SA (CLLS)   Sports Perspectives   - 08th Feb 17
The Zacks Analyst Blog Highlights: Celgene, Cellectis SA, Exelixis, Exact ...   Yahoo Finance   - 08th Feb 17
Cellectis SA (ADR) (NASDAQ:CLLS) Just Made A Big Step Forward In CAR-T   Market Exclusive   - 07th Feb 17
Research Analysts Issue Forecasts for Cellectis SA's FY2016 Earnings (CLLS)   BNB Daily (blog)   - 06th Feb 17
Cellectis SA (CLLS) Defies Sector Headwinds on Cancer Breakthrough   Schaeffers Research (blog)   - 07th May 16
A Bittersweet Outcome For Cellectis   Seeking Alpha   - 19th Nov 15
News Cellectis SA ADRCLLS   Wall Street Journal   - 21st Mar 15
Cellectis SA American Depositary Shares Quote & Summary Data   Nasdaq   - 23rd Feb 15
Cellectis SA Files $115M IPO   StreetInsider.com   - 21st Feb 15
Interactive Technical Analysis Chart Cellectis SA ( ALCLS EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Cellectis SA
ALCLS Business Profile
Cellectis, together with its subsidiaries, operates as a genome engineering company in France and internationally. The company designs and markets meganucleases and TALENs, which are tools that enable targeted modifications to DNA in the research, biomanufacturing, agro biotechnology, and therapeutic sectors; and develops and markets genome customization products used to create stable and isogenic cell lines with various characteristics and performances for use in the drug development, gene function studies, and protein production sectors. It also develops nucleases for various therapeutic applications, including correction of a genetic defect in the patient’s genome; destruction of viral genomes; or inactivation of genes to create cells with modified characteristics in the fields of cancer, viral infections, and genetic diseases. In addition, the company focuses on plant genome modification using nucleases that recognize specific DNA sequences to develop species with traits of value; and development of stem cell technology for controlling stem cell production and differentiation. It has strategic partnership agreement with Les Laboratoires Servier to develop and commercialize product candidates targeting leukemia and solid tumors. Cellectis was founded in 1999 and is based in Paris, France.